However, the combination of vvTRAP and Ad-P CSP, vvTRAP plus (vvCSP-PvCSP), significantly enhanced protective efficacy, measured as an increase in the time taken to reach 1% blood stage parasitemia compared to results with either component vaccine alone, confirming that, as with wild-type P. berghei, the combination of vivax vvTRAP and CSP antigens enhances protection against a sporozoite challenge even when equal magnitudes of adaptive humoral and cellular immune responses were induced, indicating the advantage of using two different vaccine candidates simultaneously for vaccination. The gene discussed is DNAJC5; the disease is parasitic infectious disease.